Anne-Renee Hartman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Renee Hartman has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Richard J. Wenstrup
Myriad Genetics, Inc., Salt Lake City, UT
2 shared publicationsAlexander S. Gutin
Myriad Genetics, Inc., Salt Lake City, UT
1 shared publicationCharles E. Grier
Myriad Genetic Laboratories, Inc., Salt Lake City, Utah
1 shared publicationCorinne Gustafson
Division of Thoracic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
1 shared publicationCynthia A. Frye
Myriad Genetic Laboratories, Inc., Salt Lake City, Utah
1 shared publication- David J. Harrison
School of Medicine, University of St Andrews, North Haugh, St Andrews KY16 9TF, UK
1 shared publication
Latest Publications
- Open Access
- 1 January 2015
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 10 (1) , 67-73
Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma
- 1 January 2015
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 10 (1) , 67-73
Open AccessValidation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma
- Open Access
Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer
BACKGROUND: This study assessed BRCA1 and BRCA2 mutation prevalence in an unselected cohort of patients with triple‐negative breast cancer (BC).METHODS: One hundred ninety‐nine patients were enrolled. Triple negativity was defined as neu not overexpressed by fluorescence in situ hybridization. Having given consent, patients had BRCA1 and BRCA2 full sequencing and large rearrangement analysis. Mutation prevalence was assessed among the triple‐negative BC patients and the subset of patients without a family history of breast/ovarian cancer. Independent pathological review was completed on 50 patients.RESULTS: Twenty‐one deleterious BRCA mutations were identified—13 in BRCA1 and 8 in BRCA2 (prevalence, 10.6%). In 153 patients (76.9%) without significant family history (first‐degree or second‐degree relatives with BC aged P = .0005) than expected based on previously established prevalence tables among patients unselected for pathology. BRCA1 mutation prevalence was lower, and BRCA2 mutation prevalence was higher, than previously described. Additional mutation carriers would have met new NCCN testing guidelines, underscoring the value of the updated criteria. Study data suggest that by increasing the age limit to 65 years, all carriers would have been identified. Cancer 2011;. © 2011 American Cancer Society.
Open AccessPrevalence of BRCA mutations in an unselected population of triple‐negative breast cancer
BACKGROUND: This study assessed BRCA1 and BRCA2 mutation prevalence in an unselected cohort of patients with triple‐negative breast cancer (BC).METHODS: One hundred ninety‐nine patients were enrolled. Triple negativity was defined as neu not overexpressed by fluorescence in situ hybridization. Having given consent, patients had BRCA1 and BRCA2 full sequencing and large rearrangement analysis. Mutation prevalence was assessed among the triple‐negative BC patients and the subset of patients without a family history of breast/ovarian cancer. Independent pathological review was completed on 50 patients.RESULTS: Twenty‐one deleterious BRCA mutations were identified—13 in BRCA1 and 8 in BRCA2 (prevalence, 10.6%). In 153 patients (76.9%) without significant family history (first‐degree or second‐degree relatives with BC aged P = .0005) than expected based on previously established prevalence tables among patients unselected for pathology. BRCA1 mutation prevalence was lower, and BRCA2 mutation prevalence was higher, than previously described. Additional mutation carriers would have met new NCCN testing guidelines, underscoring the value of the updated criteria. Study data suggest that by increasing the age limit to 65 years, all carriers would have been identified. Cancer 2011;. © 2011 American Cancer Society.